本帖最后由 老马 于 2013-3-13 13:43 编辑
1 S+ E! r0 X" Z6 [5 U6 n. e; J9 B1 n" Z: P7 w9 [
健择（吉西他滨）+顺铂+阿瓦斯汀( B3 G! k6 t# P0 A/ A' d
Gemzar +Cisplatin + Avastin
~1 i) ^: j/ G* h* Thttp://annonc.oxfordjournals.org/content/21/9/1804.full
+ ?9 {8 B7 X/ o2 BOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 9 {/ ~5 R4 p/ h8 H
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 7 [ X; S& }! l6 p& @" c
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 0 x0 A; e: y8 N: ^0 h' r) D9 X! j
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 284)
" g7 U6 ]3 J, {# {+ b, q3 _) z
华为网盘附件：/ _5 S: g; Z$ o b/ {6 a) Y8 `
【华为网盘】ava.JPG! Q5 f/ s& r, T. i- C4 V( {! a, _; E
|
显身卡
